disease-modifying antirheumatic drug


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

disease-modifying antirheumatic drug (DMARD)

a classification of antirheumatic agents referring to their ability to modify the course of disease, as opposed to simply treating symptoms such as inflammation and pain. Agents in this group include auranofin, azathioprine, cycloSPORINE, gold salts, hydroxychloroquine, leflunomide, methotrexate, D-penicillamine, and sulfasalazine.

disease-modifying antirheumatic drug

DMARD Rheumatology Any agent–eg, azathioprine, gold, cyclophosphamide, hydroxychloroquin, and MTX–which slows the rate of joint destruction in rheumatoid arthritis

disease-modifying antirheumatic drug

Abbreviation: DMARD
A drug that is used to treat rheumatoid arthritis and acts more slowly but more effectively than nonsteroidal anti-inflammatory drugs. Such drugs include hydroxychloroquine, methotrexate, and tumor necrosis factor inhibitors.
Synonym: slow-acting antirheumatic drug
See also: drug
References in periodicals archive ?
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying antirheumatic drugs.
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.
Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiologic disease-modifying antirheumatic drugs (DMARDs).
ENBREL also is approved for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.
The current pipeline includes many small molecule drugs and biologic therapies, as well as the first oral Disease-Modifying Antirheumatic Drug (DMARD), Tofacitinib, by Pfizer.
HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.
ENBREL is also approved for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate and for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Ankylosing spondylitis patients (n = 315), who had an inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID) or disease-modifying antirheumatic drug (DMARD), were randomized to receive either placebo or HUMIRA 40 mg subcutaneously every other week for 24 weeks.
0 for the eventual prescription of a disease-modifying antirheumatic drug (DMARD); high levels had an OR of 4.
Yet, among newly diagnosed psoriatic arthritis patients, Humira achieves a higher patient share than Enbrel in patients reaching the first and second line of disease-modifying antirheumatic drug (DMARD) therapy within one year of diagnosis.
Screening for both hepatitis C and B is a reasonable strategy in all patients who are under consideration for any disease-modifying antirheumatic drug.